
Medra AI automates routine laboratory experiments so scientists can run, repeat, and refine protocols with less manual work. The company combines robotics, computer vision, and AI (including natural language processing) in a B2B SaaS platform that executes experiments on conventional lab instruments, logs results, and adapts protocols via closed-loop feedback and intelligent error handling. Users program and adjust protocols using natural-language instructions while modular hardware and instrument integrations enable deployment across genomics, cell biology, and histology workflows. The platform targets life-science research teams seeking to scale experimentation and accelerate iterative discovery.

Medra AI automates routine laboratory experiments so scientists can run, repeat, and refine protocols with less manual work. The company combines robotics, computer vision, and AI (including natural language processing) in a B2B SaaS platform that executes experiments on conventional lab instruments, logs results, and adapts protocols via closed-loop feedback and intelligent error handling. Users program and adjust protocols using natural-language instructions while modular hardware and instrument integrations enable deployment across genomics, cell biology, and histology workflows. The platform targets life-science research teams seeking to scale experimentation and accelerate iterative discovery.
What they do: Automates wet-lab experiments with a Physical AI + Scientific AI platform combining robotics, computer vision, and NLP
Founded: 2021
Headcount (approx.): 31
Latest disclosed raise: Series A $52M (announced Dec 11, 2025)
Laboratory automation and scientific workflow acceleration for genomics, cell biology, and histology
2021
Software Development
52000000
Announced Series A to scale deployments and build an autonomous lab; participation reported from Lux Capital, Neo, NFDG, Catalio Capital Management, Menlo Ventures, and others.
Earlier pre-seed/seed rounds and multiple investors reported (investor list includes Anthology Fund, Catalio Capital Management, Forward Deployed Venture Capital, Fusion Fund, Human Capital, Lux Capital, Mei Z., Menlo Ventures, NFDG Ventures, Nat Friedman, Neo, Palm Drive Capital, Patrick David Hsu, PharmStars, Seven Seven Six), with amounts/dates not fully specified in the provided evidence.
“Company raised a $52M Series A led by Human Capital with participation from established VC firms and angel/backer investors, indicating venture‑backed growth-stage financing.”
| Company |
|---|